HT
CORT icon

Headlands Technologies’s Corcept Therapeutics CORT Stock Holding History

Headlands Technologies’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,117
Closed -$56.3K – 1202
2024
Q4 		$56.3K Sell
1,117
-6,041
-84% -$317K 0.01% 793
2024
Q3 		$331K Buy
7,158
+6,871
+2,394% +$244K 0.04% 409
2024
Q2 		$9.32K Sell
287
-132
-32% -$3.62K ﹤0.01% 978
2024
Q1 		$10.6K Sell
419
-1,033
-71% -$24.4K ﹤0.01% 1021
2023
Q4 		$47.2K Buy
+1,452
New +$39.9K 0.01% 532

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Headlands Technologies's CORT Position: Q1 2025 in Review

Headlands Technologies sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 1,117 shares — an estimated $56.3K sold.

Headlands Technologies first reported a position in CORT in Q4 2023 and held it in 5 quarters. The position peaked at $331K in Q3 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

  • Headlands Technologies reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Headlands Technologies sold 1,117 Corcept Therapeutics shares in Q1 2025, an estimated $56.3K.
  • Headlands Technologies first reported a position in Corcept Therapeutics in Q4 2023 and held it in 5 quarters.
  • Headlands Technologies's Corcept Therapeutics position peaked at $331K in Q3 2024.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Headlands Technologies's 13F filing for Q1 2025, filed 9 May 2025.